

Age-Related Macular Degeneration Market to Exceed \$16.2 Billion by 2033 at 5% CAGR

PORTLAND, OR, UNITED STATES,
November 21, 2024 /

EINPresswire.com/ -- Increase in prevalence of age-related macular degeneration cases, rise in geriatric population, and growth in clinical research and development are the major factors which drive the global market growth.

Allied Market Research published a report, titled, "[Age Related Macular Degeneration Market](#) by Drug Type (Aflibercept, Ranibizumab and Others),

Disease Type (Wet Age Related Macular Degeneration (AMD), Dry Age Related Macular Degeneration (AMD)) and Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Online Pharmacy): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the age related macular degeneration market was valued at \$10.0 billion in 2023, and is estimated to reach \$16.2 billion by 2033, growing at a CAGR of 5% from 2024 to 2033.


□□□ □ □□□□□□ □□□□ □□ □□□□ □□□□□□: <https://www.alliedmarketresearch.com/request-sample/3538>

Prime determinants of growth

Rise in prevalence of age-related macular degeneration cases and rise in geriatric population are the major factors that drive the growth of the age-related macular degeneration market. However, high cost of treatment hinders the market growth. Moreover, technological advancements offer remunerative opportunities for the expansion of the global age-related macular degeneration market.

Report coverage & details

Report Coverage



Age-Related Macular Degeneration Market growth analysis

Details

Forecast Period

2024–2033

Base Year

2023

Market Size in 2023

\$9.9 billion

Market Size in 2033

\$16.2 billion

CAGR

5.0%

No. of Pages in Report

216

Segments Covered

Drug Type, Disease Type, Distribution Channel, and Region

Drivers

Increase in incidences of age-related macular degeneration (AMD) across the globe

Increase in geriatric population

Growth in government initiatives

Opportunities

Increase in number of pipelines drug

Restraints

High cost of treatment

Segment Highlights

The aflibercept drug are widely used

By drug type, the Aflibercept (Eylea) segment is widely used for treating wet age-related macular degeneration (AMD) due to its effectiveness in inhibiting vascular endothelial growth factor (VEGF) . This action prevents abnormal blood vessel growth and leakage in the eye, helping to maintain vision and slow disease progression. Its proven efficacy and safety profile make it a preferred choice among clinicians.

Prevalence of Wet Age-Related Macular Degeneration (AMD)

By disease type, the wet age-related macular degeneration (AMD) segment has a significant market share owing to it being increasingly prevalent, particularly among the aging population. Characterized by abnormal blood vessel growth under the retina, it leads to rapid vision loss. The rising incidence highlights the need for effective treatments, such as anti-VEGF therapies, to manage and slow disease progression.

Hospitals pharmacies are the major distributors

By distribution channel, the hospital pharmacies segment plays a pivotal role in distributing drugs for age-related macular degeneration (AMD), ensuring timely access for patients. They manage inventory, fill prescriptions, and provide counseling. AMD drugs, like anti-VEGF injections, require careful handling and administration. Hospital pharmacies ensure proper storage and delivery, optimizing treatment outcomes for patients with AMD, a condition affecting central vision in older adults.

Regional Outlook

In North America and Europe, the age-related macular degeneration (AMD) drugs market is robust due to high prevalence and advanced healthcare infrastructure. Asia-Pacific shows promising growth driven by rising elderly population and improving healthcare access. Latin America and Middle East/Africa regions exhibit steady growth, supported by increasing awareness and healthcare investments.

Players

Regeneron Pharmaceuticals Inc.

Novartis AG

F. Hoffmann-La Roche Ltd.

Biogen

Bayer AG

Coherus Biosciences Inc

Sanofi

Apellis Pharmaceuticals

Bausch Health Companies Inc.

Ionis Pharmaceuticals, Inc

The report provides a detailed analysis of these key players in the global age-related macular degeneration market. These players have adopted different strategies such as expansion, product approval, product launch and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.

Recent Industry Development

In September 2021, Samsung Bioepis Co., Ltd., and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab) for the treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) .

In January 2022, Roche announced that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of neovascular or wet age-related macular degeneration (nAMD) and diabetic macular edema (DME) . Neovascular AMD and DME are two leading causes of vision loss across the globe.

□□□□□□ □□□□□□ □□□□□□: <https://www.alliedmarketresearch.com/purchase-enquiry/3538>

Sachin Bhandare

Allied Market Research INC

+91 81490 46454

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/762521071>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.